AcquisitionsKnight announced that it will acquire the Paladin business unit from Endo Inc., including $20M of inventory.
Company PerformanceKnight Therapeutics reported a strong quarterly performance, beating estimates and increasing its guidance.
Product LaunchesKnight Therapeutics plans to launch over 10 new drugs, expected to significantly increase revenue and gross margin.